Drugs / JNJ-87890387
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06178614 | Dec 2023 → Mar 2027 expected | neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-87890387 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06178614 ↗ |
| Target | ENPP3 | “Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 (ENPP3) x CD3” NCT06178614 ↗ |